Cited by 373Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchViral-associated cancers and disorders

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Open access

Morschhauser, Franck, Fowler, Nathan H., Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M. Lia, Fruchart, Christophe, Libby, Edward N., Casasnovas, Rene-Olivier, Flinn, Ian W., Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L., Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicolas, Le Gouill, Steven, Pica, Gian M., Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H., Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A.·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1805104PMC PMC11003525

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma. METHODS: We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Patients were randomly assigned to receive one of the two regimens, followed by maintenance monotherapy with rituximab. Treatment with rituximab plus lenalidomide consisted of 18 cycles of the two drugs, followed by rituximab maintenance therapy every 8 weeks for 12 cycles (six additional doses). Treatment with rituximab plus chemotherapy consisted of the investigator's choice of one of three rituximab-based regimens, followed by maintenance monotherapy with rituximab every 8 weeks for 12 cycles. The primary end points were complete response (confirmed or unconfirmed) at 120 weeks and progression-free survival. RESULTS: A total of 1030 patients were randomly assigned to receive rituximab plus lenalidomide (513 patients) or rituximab plus chemotherapy (517 patients). The rate of confirmed or unconfirmed complete response at 120 weeks was similar in the two groups: 48% (95% confidence interval [CI], 44 to 53) in the rituximab-lenalidomide group and 53% (95% CI, 49 to 57) in the rituximab-chemotherapy group (P=0.13). The interim 3-year rate of progression-free survival was 77% (95% CI, 72 to 80) and 78% (95% CI, 74 to 82), respectively. A higher percentage of patients in the rituximab-chemotherapy group had grade 3 or 4 neutropenia (32% vs. 50%) and febrile neutropenia of any grade (2% vs. 7%), and a higher percentage of patients in the rituximab-lenalidomide group had grade 3 or 4 cutaneous reactions (7% vs. 1%). CONCLUSIONS: Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and rituximab plus chemotherapy (with both regimens followed by rituximab maintenance therapy). The safety profile differed in the two groups. (Funded by Celgene; RELEVANCE ClinicalTrials.gov numbers, NCT01476787 and NCT01650701 , and EudraCT number, 2011-002792-42 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1805104

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Rummel, M., Niederle, N., Maschmeyer, G., Banat, G.-A., von Grünhagen, U., Losem, C. J., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,512
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Salles, G., Seymour, J. F., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,075
Self-citation
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3488 · Cited by 907
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R. E., Davies, A. J., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E. H., Sangha, R. S., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 824
Self-citation
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
Brice, P., Bastion, Y., Lepage, É., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah-Fisch, I. M., & Solal‐Céligny, P. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1110 · Cited by 646
Self-citation
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., Macdonald, D. A., Hertzberg, M., Kwan, Y., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 644
Self-citation
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate Tcells by inducing degradation of Tcell repressors Ikaros and Aiolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 1

Fowler N. Extended dosing lenalidomide with intensified rituximab in untreated indolent NHL. Hematol Oncol 2015;33:200-201. poster.

Sorted by citations

Items 101–200 of 373

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q
Park, I., Phan, T. M., & Fang, J. (2021) · Cancers · doi:10.3390/cancers13205084 · Cited by 15
Lymphomas in pregnancy
Pirosa, M. C., & Peccatori, F. A. (2023) · Hematological Oncology · doi:10.1002/hon.3150 · Cited by 15
Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma
Cox, M. C., Lapenta, C., & Santini, S. M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02577-w · Cited by 14
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Lymphomas: Current Status and Future Directions
Chávez, J. C., Yassine, F., Sandoval-Sus, J. D., & Kharfan‐Dabaja, M. A. (2021) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2020-0021 · Cited by 16
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
Cherng, H.-J. J., Alig, S., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., Turturro, F., Hagemeister, F. C., Craig, A. F. M., Macaulay, C. W., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008174 · Cited by 15
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
Sawalha, Y., & Maddocks, K. J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s219449 · Cited by 14
Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review
Luttwak, E., Gurevich‐Shapiro, A., Azem, F., Lishner, M., Klieger, C., Herishanu, Y., Perry, C., & Avivi, I. M. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100831 · Cited by 14
Immunotherapy in indolent Non-Hodgkin's Lymphoma
Amhaz, G., Bazarbachi, A. A., & Cheikh, J. E. (2022) · Leukemia Research Reports · doi:10.1016/j.lrr.2022.100325 · Cited by 14
High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease
Nota, S. P. F. T., Al-Sukaini, A., Patel, S. S., Sabbatino, F., Nielsen, G. P., Deshpande, V., Yearley, J. H., Ferrone, S., Wang, X., & Schwab, J. H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.598001 · Cited by 15
Novel treatment approaches and future perspectives in follicular lymphoma
Sutamtewagul, G., & Link, B. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718820510 · Cited by 13
Recent landmark studies in follicular lymphoma
Sorigué, M., & Sancho, J. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.03.006 · Cited by 13
Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma
Strati, P., Jain, P., Johnson, R. J., Forbes, S. G., Feng, L., Samaniego, F., Rodriguez, M. A., Fayad, L., Hagemeister, F. C., Westin, J. R., et al. (2020) · Blood · doi:10.1182/blood.2020007994 · Cited by 13
Self-citation
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
Heß, G., Wagner, K., Keller, U. B., Rosée, P. G. L., Atta, J., Hübel, K., Lerchenmueller, C., Schoendube, D., Witzens‐Harig, M., Ruckes, C., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000398 · Cited by 13
A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Strati, P., Feng, L., Tyshevich, A., Shavronskaya, D., Alesse, J., English, N., Sheehan, E., Syzrantsev, N., Nesmelov, A. A., Zhuang, T., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1826 · Cited by 13
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
Marques-Piubelli, M. L., Parra, E. R., Feng, L., Soto, L. M. S., Gallardo, M., Gouni, S., Samaniego, F., Noorani, M., Hagemeister, F. B., Westin, J. R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007104 · Cited by 12
Self-citation
Treatment of indolent lymphoma
Jeong, S. H. (2022) · Blood Research · doi:10.5045/br.2022.2022054 · Cited by 12
Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma
Ollila, T. A., & Olszewski, A. J. (2021) · Cancer Management and Research · doi:10.2147/cmar.s267258 · Cited by 14
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies
Smyth, E., Cheah, C. Y., & Seymour, J. F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102510 · Cited by 13
Follicular Lymphoma
Welaya, K. Y., & Casulo, C. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.03.003 · Cited by 12
Blinatumomab: a novel therapy for the treatment of non-Hodgkin’s lymphoma
Bukhari, A. A., & Lee, S. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1676717 · Cited by 12
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
Desai, S. H., LaPlant, B. R., Macon, W. R., King, R. L., Wang, Y., Inwards, D. J., Micallef, I. N., Johnston, P. B., Porrata, L. F., Ansell, S. M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00542-z · Cited by 12
Drug-induced olfactory and gustatory dysfunction: Analysis of FDA adverse events reporting system
Debbaneh, P. M., McKinnon, L., Haidari, M., & Liang, J. Z. (2023) · Auris Nasus Larynx · doi:10.1016/j.anl.2022.12.012 · Cited by 11
Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review
Rivero, A., Mozas, P., Magnano, L., & López‐Guillermo, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170394 · Cited by 11
Self-citation
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study
Gordon, M. J., Feng, L., Strati, P., Lee, H. J., Hagemeister, F. B., Westin, J. R., Samaniego, F., Marques-Piubelli, M. L., Vázquez, F. J. V., Parra, E. R., et al. (2023) · Cancer · doi:10.1002/cncr.35114 · Cited by 11
Self-citation
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Stathis, A., Mey, U., Schär, S., Hitz, F., Pott, C., Mach, N., Krasniqi, F., Novak, U., Schmidt, C., Hohloch, K., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006520 · Cited by 11
Current trends in diagnosis and management of follicular lymphoma.
Gupta, G., Garg, V., Mallick, S., & Gogia, A. (2022) · PubMed Central · Cited by 11
How I manage patients with follicular lymphoma
Casulo, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.16011 · Cited by 11
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma
Nastoupil, L. J. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00617-5 · Cited by 10
Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach
Chen, C.-J. J., Choi, M. Y., & Heyman, B. M. (2023) · Cancers · doi:10.3390/cancers15184483 · Cited by 10
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial
Ladetto, M., Tavarozzi, R., Zanni, M., Evangelista, A., Ferrero, S., Tucci, A., Botto, B., Bolis, S. A. M., Volpetti, S., Zilioli, V. R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.095 · Cited by 10
Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients
Elsayad, K., Reinartz, G., Oertel, M., Rehn, S., Eismann, J., Scobioala, S., Berssenbrügge, H., Eter, N., Weishaupt, C., Schmidt, H., et al. (2019) · Strahlentherapie und Onkologie · doi:10.1007/s00066-019-01538-2 · Cited by 10
Advances in Treatment of Follicular Lymphoma
Luminari, S., Trotman, J., & Federico, M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000444 · Cited by 10
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma
Michot, J., Buet-Elfassy, A., Annereau, M., Lazarovici, J., Danu, A., Sarkozy, C., Chahine, C., Bigenwald, C., Bosq, J., Rossignol, J., et al. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.109 · Cited by 10
Self-citation
Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment
Watanabe, T. (2021) · Cancers · doi:10.3390/cancers14010141 · Cited by 11
Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice
López, C., Mozas, P., López‐Guillermo, A., & Beà, S. (2022) · Hemato · doi:10.3390/hemato3040041 · Cited by 14
Self-citation
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Ubieto, A. J., Martín-Muñoz, A., Poza, M., Dorado, S., García-Ortiz, A., Revilla, E., Sarandeses, P., Ruiz‐Heredia, Y., Baumann, T., Rodríguez, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188818 · Cited by 10
Recent advances in treatment of nodal and gastrointestinal follicular lymphoma
Watanabe, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i23.3574 · Cited by 10
Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules
Banchi, M., Cox, M. C., & Bocci, G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216900 · Cited by 10
Targeting CD20: teaching an old dog new tricks
Sharman, J. P. (2019) · Hematology · doi:10.1182/hematology.2019000031 · Cited by 9
Lymphocyte‐monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low‐grade B‐cell lymphoma
Shimono, J., Izumiyama, K., Ito, S., Tsutsmi, Y., Kondo, T., Kakinoki, Y., & Teshima, T. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13216 · Cited by 10
The treatment of marginal zone lymphoma
Alderuccio, J. P., & Noy, A. (2025) · Blood · doi:10.1182/blood.2024028269 · Cited by 9
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?
Casulo, C., & Sehn, L. H. (2025) · Blood · doi:10.1182/blood.2024026018 · Cited by 9
Self-citation
Advances in the multi-omics landscape of follicular lymphoma
Xu, T., Zheng, Z., & Zhao, W. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.80401 · Cited by 9
Choosing the right pharmacotherapy for non-Hodgkin’s lymphoma: does one size fit all?
Juhaishi, T. A., & Yazbeck, V. Y. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1582643 · Cited by 9
Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system
Li, W., Liu, C., Zhang, Z., Cai, Z., Lv, T., Zhang, R., Zuo, Y., & Chen, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1443555 · Cited by 9
Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials
Malmon, S., Elsensohn, M., Thiéblemont, C., Morschhauser, F., Casasnovas, O., André, M. P. E., Gouill, S. L., Tabaa, Y. A., Durand, P. B., Bailly, C., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07176-4 · Cited by 8
Self-citation
Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?
Cancemi, G., Campo, C., Caserta, S., Rizzotti, I., & Mannina, D. (2025) · Cancers · doi:10.3390/cancers17101602 · Cited by 8
Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
Willard, P. J., McKay, J., & Yazbeck, V. Y. (2021) · Leukemia Research Reports · doi:10.1016/j.lrr.2021.100275 · Cited by 8
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
Nylund, P., Nikkarinen, A., Ek, S., & Glimelius, I. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1373269 · Cited by 8
Advancements in the Management of Follicular Lymphoma: A Comprehensive Review
Merryman, R. W., Mehtap, Ö., & LaCasce, A. S. (2024) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2024.2024.0015 · Cited by 8
One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?
Roschewski, M. J., & Hill, B. T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239065 · Cited by 8
Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers
Aoki, T., Savage, K. J. J., & Steidl, C. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01761 · Cited by 7
Long‐term efficacy and safety of chemotherapy‐free first‐line iodine‐131‐rituximab radioimmunotherapy of follicular lymphoma
Kesavan, M., Zammar, G., McQuillan, J. T., MACDONALD, W. B., Turner, J. H., & McQuillan, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17758 · Cited by 8
Follicular lymphoma: an update on biology and optimal therapy
Fischer, L., & Dreyling, M. H. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2174804 · Cited by 8
First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna
Kiesewetter, B., Simonitsch‐Klupp, I., Mayerhoefer, M. E., Dolak, W., Lukas, J., & Raderer, M. (2020) · Cancers · doi:10.3390/cancers12123533 · Cited by 8
Functional plasticity and recurrent cell states of malignant B cells in follicular lymphomaPreprint
Attaf, N., Dong, C., Gil, L., Cervera-Marzal, I., Gharsalli, T., Navarro, J., Mboumba, D.-L., Chasson, L., Lemonnier, F., Gaulard, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487285 · Cited by 9
Antibody-Based Therapies for Peripheral T-Cell Lymphoma
Shafagati, N., Paul, S., Rozati, S., & Sterling, C. H. (2024) · Cancers · doi:10.3390/cancers16203489 · Cited by 7
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update
Kimby, E. K., Schär, S., Pirosa, M. C., Vanazzi, A., Mey, U., Rauch, D., Wahlin, B. E., Hitz, F., Hernberg, M., Johansson, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014840 · Cited by 7
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
Strati, P., Feng, L., Westin, J. R., Nair, R. K., Fayad, L., Rodriguez, M. A., Chihara, D., Malpica, L., Henderson, J. M., Gallardo, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62509-z · Cited by 7
The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma
Schweitzer, J., Hoffman, M., & Graf, S. A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2043273 · Cited by 7
Clinical applications of circulating tumor DNA in indolent B-cell lymphomas
Lakhotia, R., & Roschewski, M. J. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.06.003 · Cited by 7
Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance
Tobin, J. W. D., Hapgood, G., Johnston, A. M., Cheah, C. Y., Lee, S. T., Trotman, J., Inam, S., Campbell, B. A., Norris, D., MacManus, M. P., et al. (2024) · Internal Medicine Journal · doi:10.1111/imj.16454 · Cited by 7
Building the future management of follicular lymphoma with T-cell–redirecting strategies
Iacoboni, G., & Morschhauser, F. (2024) · Blood · doi:10.1182/blood.2024025699 · Cited by 7
Self-citation
Management of relapsed follicular lymphoma
Rodgers, T. D., & Barr, P. M. (2021) · Annals of Lymphoma · doi:10.21037/aol-21-1 · Cited by 7
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
Minson, A. G., Tam, C. S. L., Dickinson, M. J., & Seymour, J. F. (2022) · Cancers · doi:10.3390/cancers14051276 · Cited by 8
Immunomodulatory Agents in Follicular Lymphoma
Ysebaert, L., & Morschhauser, F. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.02.007 · Cited by 7
Self-citation
Novel Therapy Approaches to Follicular Lymphoma
Northend, M., & Townsend, W. M. (2021) · Drugs · doi:10.1007/s40265-020-01446-1 · Cited by 7
Novel synthetic drugs for the treatment of non-Hodgkin lymphoma
Manji, F., Puckrin, R., & Stewart, D. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1902988 · Cited by 7
Real-World Evidence of Clinical Outcomes in Precision Radionuclide Oncology: The NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer
Turner, J. H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200312141347 · Cited by 7
The future of follicular lymphoma management: strategies on the horizon
Mulvey, E. C., Rutherford, S. C., & Leonard, J. P. (2025) · Blood · doi:10.1182/blood.2024026017 · Cited by 6
Mosunetuzumab for the treatment of follicular lymphoma
Labanca, C., Martino, E. A., Vigna, E., Bruzzese, A., Mendicino, F., Luca, P. D., Lucia, E., Olivito, V., Fragliasso, V., Neri, A., et al. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2404079 · Cited by 6
Bridging clinicopathologic features and genetics in follicular lymphoma: Towards enhanced diagnostic accuracy and subtype differentiation
Bosch‐Schips, J., Parisi, X., Climent, F., & Vega, F. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.105676 · Cited by 6
Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis
Chihara, D., Yang, S., Chawla, S. B., Zhang, G., Wang, A., Yu, J., Arnette, D., Navarro, F. R., Blædel, J., & Mutebi, A. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100080 · Cited by 6
Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
Feugier, P., & Filliatre‐Clement, L. (2019) · F1000Research · doi:10.12688/f1000research.16686.1 · Cited by 6
Self-citation
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma
Izutsu, K., Minami, Y., Fukuhara, N., Terui, Y., Jo, T., Yamamoto, G., Ishikawa, T., Kobayashi, T., Kiguchi, T., Nagai, H., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02802-y · Cited by 6
Self-citation
Targeted Therapies for Follicular Lymphoma
Girard, J., Karimi, Y. H., Carty, S. A., Wilcox, R. A., Kaminiski, M. S., Malek, S. N., & Phillips, T. J. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00614-8 · Cited by 6
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Tuscano, J. M., Poh, C., Kaesberg, P. R., Luxardi, G., Merleev, A. A., Marusina, A. I., Brunson, A. M., Rosenberg, A. S., Jonas, B. A., & Maverakis, E. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4622 · Cited by 6
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation
Bachy, E., Rufibach, K., Parreira, J. M., Launonen, A., Nielsen, T. G., & Hackshaw, A. K. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01738-2 · Cited by 6
An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
Yılmaz, U., Salihoğlu, A., & Soysal, T. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281614 · Cited by 6
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis
Luan, D., Fatola, T., Toure, A., Flowers, C. R., Link, B. K., Friedberg, J. W., Cohen, J. B., Kahl, B. S., Lossos, I. S., Nastoupil, L. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007687 · Cited by 6
A brief rituximab, bendamustine, mitoxantrone (R‐BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
Boccomini, C., Ladetto, M., Rigacci, L., Puccini, B., Rattotti, S., Volpetti, S., Ferrero, S., Chiarenza, A., Freilone, R., Novo, M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17283 · Cited by 6
Targeted Treatment of Follicular Lymphoma
Nath, K., & Gandhi, M. K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020152 · Cited by 7
High‐risk follicular lymphoma: Treatment options
Kahl, B. S. (2021) · Hematological Oncology · doi:10.1002/hon.2853 · Cited by 6
Follicular lymphoma: An update on diagnosis, prognosis, and management
Mozas, P., Sorigué, M., & López‐Guillermo, A. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.03.016 · Cited by 6
Self-citation
Myeloid Toxicity of Radionuclide Cancer Therapy
Kesavan, M., & Turner, J. H. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2021.0286 · Cited by 6
Follicular lymphomas in vulnerable/older patients
Tucci, A., & Rossi, G. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000555 · Cited by 6
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Maurer, M. J., Procházka, V., El‐Galaly, T. C., Flowers, C. R., Villa, D. R., Bachy, E., Cahn, E. J., Fournier, M., Larson, M. C., Dietrich, C. E., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00892 · Cited by 5
Self-citation
Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches
Martino, E. A., Caserta, S., Skafi, M., Alvaro, M. E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., et al. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70105 · Cited by 5
Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026
Peñalver, F., Magnano, L., Álvarez, S. A., Jiménez-Ubieto, A., López‐Guillermo, A., & Sancho, J. (2026) · Cancers · doi:10.3390/cancers18030395 · Cited by 5
Self-citation
Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study
Gui, L., Xie, Z., Qin, Y., Liu, P., Yang, J., Chen, X., Li, Z., Tao, R., & Shi, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14370-y · Cited by 5
Towards a chemo‐free approach for follicular lymphoma
Luminari, S., Barbieri, E., & Nizzoli, M. E. (2025) · British Journal of Haematology · doi:10.1111/bjh.70126 · Cited by 5
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
Pongas, G. N., & Cheson, B. D. (2021) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s267569 · Cited by 5
A roadmap for clinical trial design in marginal zone lymphoma
Alderuccio, J. P., Habermann, T. M., Kuker, R. A., Moskowitz, C. H., Zelenetz, A. D., & Lossos, I. S. (2022) · American Journal of Hematology · doi:10.1002/ajh.26706 · Cited by 5
Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma
Weiss, J. M., & Phillips, T. J. (2024) · Cancers · doi:10.3390/cancers16091724 · Cited by 5
Rituximab induced lung injury
Chari, R. R., Abdelghany, Y., Purcell, M., & Kenaa, B. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03802-x · Cited by 5
Precision medicine in follicular lymphoma: Focus on predictive biomarkers
Sorigué, M., Cañamero, E., & Sancho, J. (2020) · Hematological Oncology · doi:10.1002/hon.2781 · Cited by 7
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial
Rai, S., Inoue, H., Hanamoto, H., Matsuda, M., Maeda, Y., Wada, Y., Haeno, T., Watatani, Y., Kumode, T., Hirase, C., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03148-0 · Cited by 5
Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials
Bommier, C., Ruggiu, M., Monégier, A., Zucca, E., Thiéblemont, C., & Lambert, J. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2032038 · Cited by 5
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study
Barraclough, A., Lee, S. T., Burgess, M. L., Churilov, L. P., Chong, G., Lee, D., Gilbertson, M., Fancourt, T., Manos, K., Ritchie, D. S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015487 · Cited by 4
Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma
Poza, M., Martín-Muñoz, A., López‐Pereira, P., Figaredo, G., Zamanillo, I., Íñiguez, R., Oliveira, A. C., Baumann, T., Izquierdo, A. R., Grande, C., et al. (2025) · Cancers · doi:10.3390/cancers17071065 · Cited by 4

Authors: Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., Haioun, C., Maisonneuve, H., Ysebaert, L., Bartlett, N. L., Bouabdallah, K., Brice, P., Ribrag, V., Daguindau, N., Le Gouill, S., Pica, G. M., Martin Garcia-Sancho, A., López-Guillermo, A., Larouche, J.-F., Ando, K., Gomes da Silva, M., André, M., Zachée, P., Sehn, L. H., Tobinai, K., Cartron, G., Liu, D., Wang, J., Xerri, L., & Salles, G. A.
Affiliations: Centre National de la Recherche Scientifique (FR)
From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d’Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and...
ORCID: Morschhauser, Franck
Fowler, Nathan H.
Feugier, Pierre
Tilly, Hervé
Palomba, M. Lia
Fruchart, Christophe
Flinn, Ian W.
Bartlett, Nancy L.
Bouabdallah, Kamal
Brice, Pauline
Ribrag, Vincent
Larouche, Jean-François
Ando, Kiyoshi
André, Marc
Zachée, Pierre
Sehn, Laurie H.
Tobinai, Kensei
Cartron, Guillaume
Wang, Jianming
Xerri, Luc
Salles, Gilles A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-09-06
Volume: 379
Issue: 10
Pages: 934-947
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1805104
PMC: PMC11003525
OpenAlex: W2891543930
Cited by: 373
References: 30
Citations by year: 2026: 17 · 2025: 52 · 2024: 38 · 2023: 37 · 2022: 52 · 2021: 62 · 2020: 58 · 2019: 51 · 2018: 5
FWCI: 33.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
HAL (submittedVersion)
Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
DIAL (Catholic University of Leuven) (submittedVersion)
Funders: Celgene
Topics: Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords: follicular lymphoma, rituximab, lenalidomide, previously untreated lymphoma, rituximab plus chemotherapy, maintenance therapy, complete response, progression-free survival, neutropenia, skin reactions, immunomodulatory therapy, B-cell non-Hodgkin lymphoma, safety and tolerability
MeSH terms: Rituximab, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neutropenia, Skin Diseases, Thalidomide, Survival Rate, Disease-Free Survival, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks